(NASDAQ: GNLX) Genelux's forecast annual revenue growth rate of 2,691.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Genelux's revenue in 2025 is $8,000.On average, 1 Wall Street analysts forecast GNLX's revenue for 2026 to be $165,783,288, with the lowest GNLX revenue forecast at $165,783,288, and the highest GNLX revenue forecast at $165,783,288. On average, 1 Wall Street analysts forecast GNLX's revenue for 2027 to be $2,528,195,142, with the lowest GNLX revenue forecast at $2,528,195,142, and the highest GNLX revenue forecast at $2,528,195,142.
In 2028, GNLX is forecast to generate $6,234,142,393 in revenue, with the lowest revenue forecast at $6,234,142,393 and the highest revenue forecast at $6,234,142,393.